International Journal of Chronic Obstructive Pulmonary Disease最新文献

{"title":"Acupuncture for Chronic Obstructive Pulmonary Disease: A 38-Year Bibliometric Landscape of Global Research Trends and Knowledge Evolution (1986-2024).","authors":"Kaiting Wu, Chen Ruan","doi":"10.2147/COPD.S531611","DOIUrl":"10.2147/COPD.S531611","url":null,"abstract":"<p><strong>Background: </strong>Despite growing interest in acupuncture as a complementary therapy for chronic obstructive pulmonary disease (COPD), comprehensive analyses of its global research trajectory, disciplinary convergence patterns, and geopolitical contributions remain unexplored. This study addresses this gap by mapping the intellectual and geopolitical architecture of acupuncture-COPD research over nearly four decades, a period chosen to capture the significant developments in acupuncture's global recognition since the late 1980s, when traditional medicine began to gain more global attention.</p><p><strong>Methods: </strong>We conducted a longitudinal bibliometric analysis of 299 publications indexed in the Web of Science Core Collection (1986-2024). Employing Bradford's and Lotka's laws, co-citation networks, and keyword co-occurrence clustering, we systematically evaluated temporal productivity trends, institutional/country contributions, citation dynamics, and thematic evolution using SciMAT, VOSviewer, and bibliometrix R-package. (Response to Editor's Comment 1).</p><p><strong>Results: </strong>Research productivity followed a triphasic trajectory: a dormant phase (1986-2000, ≤2 articles/year), a stabilization phase (2001-2014, +4% annual growth), and an exponential growth phase (2015-2024, 13 articles/year), closely aligned with global policy shifts in traditional medicine. China emerged as the dominant contributor (338 articles, 64.2% global output), yet Canada demonstrated superior research impact (108 citations/article), highlighting a productivity-impact paradox. Mechanistic investigations into neuroimmunological pathways, particularly μ-opioid receptor modulation (centrality 0.74), became central research pillars, reinforced by biomarker-correlated clinical trials showing β-endorphin-FEV1 interactions (r = 0.526, p = 0.008). Persistent translational gaps were evident, with 63% of RCTs relying on subjective \"deqi\" assessments despite technological advances in objective acupuncture monitoring.</p><p><strong>Conclusion: </strong>This analysis reveals critical asymmetries between Eastern research productivity and Western methodological innovation in acupuncture-COPD research. This analysis suggests a need for a threefold strategy integrating multiscale neuroimaging validation, globalized trial standardization through CONSORT-Acupuncture frameworks, and equitable North-South knowledge exchange to address the growing burden of COPD-related dyspnea in aging populations.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2393-2408"},"PeriodicalIF":2.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Laser System-Assisted CT-Guided Percutaneous Transthoracic Lung Biopsy in Patients with COPD Combined with Pulmonary Nodules.","authors":"Chao Li, Xiao Hu, Cheng Li, Gang Jiang, Yong Liang Jiang","doi":"10.2147/COPD.S530756","DOIUrl":"10.2147/COPD.S530756","url":null,"abstract":"<p><strong>Objective: </strong>The diagnosis and management of pulmonary nodules in patients with COPD are challenging, as these nodules may represent either lung cancer or other pulmonary diseases. This study aims to evaluate the efficiency of a novel laser systems (LGS)-assisted CT-guided percutaneous lung biopsy in COPD patients with pulmonary nodules.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the data of 60 COPD patients with pulmonary nodules. Thirty patients (n=30) underwent CT-guided percutaneous transthoracic lung biopsy assisted by LGS, while the remaining 30 (n=30) underwent conventional manual CT-guided percutaneous transthoracic lung biopsy. The surgical time, number of punctures, CT scan frequency, and complications were compared between the two groups.</p><p><strong>Results: </strong>No significant differences were found between the two groups in terms of clinical characteristics, lesion size, location, puncture depth, or nodule nature. Compared to the traditional method, LGS-assisted CT-guided percutaneous lung biopsy significantly reduced the number of CT scans (2.3 ± 0.5 vs 3.2 ± 0.6, P < 0.001) and the average procedure time (12.6 ± 2.7 min vs 25.1 ± 3.4 min, P < 0.001). Additionally, the total intraoperative time per procedure was significantly reduced (25.1 ± 3.4 min vs 45.9 ± 8.8 min, P < 0.001). With the use of LGS, 73% (22/30) of the procedures hit the target on the first needle insertion, compared to only 6.7% (2/30) in the conventional group. Furthermore, there was no significant difference in the incidence of complications between the two groups.</p><p><strong>Conclusion: </strong>Compared to the traditional method, the use of LGS improved puncture efficiency in COPD patients, reduced the need for needle adjustments, and effectively shortened the procedure time.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2371-2379"},"PeriodicalIF":2.7,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Telemonitoring on Moderate and Severe Exacerbations in Patients with COPD: Pooled Analysis of Two Randomized Controlled Trials in Denmark.","authors":"Charlotte Hyldgaard, Thomas Ringbæk, Frank Dyekjær Andersen, Ejvind Frausing Hansen, Michael Skov Jensen, Morten Fenger-Grøn, Christian Trolle, Charlotte Suppli Ulrik","doi":"10.2147/COPD.S528852","DOIUrl":"10.2147/COPD.S528852","url":null,"abstract":"<p><strong>Background: </strong>Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are serious events with high morbidity and mortality. Previous studies investigated telemonitoring as a tool for prevention of hospitalizations with ambiguous results. The aim of the present study was to combine data from two randomized controlled trials conducted in Denmark in similar healthcare settings to explore number of hospitalizations for COPD, days of admission, and exacerbations treated outside hospitals.</p><p><strong>Methods: </strong>Recruitment took place during hospitalization for AECOPD and from outpatient COPD clinics. Patients were equally randomized to telemonitoring (N=251) in addition to usual care for six months or usual care alone (N=252). We used a negative binomial regression model with between-group comparisons expressed as incidence rate ratios (IRRs) for assessment of hospitalizations, admission days and moderate exacerbations and Kaplan-Meier time-to-event analysis for assessment of time to first COPD hospitalization.</p><p><strong>Results: </strong>No significant differences between the two studies were identified. In combined analyses, numerically fewer hospitalizations (IRR 0.85, 95% CI 0.62-1.17) and hospitalization days (IRR 0.72, 95% CI 0.42-1.23) were seen in the telemonitoring group, but the findings did not reach statistical significance whereas treatment for moderate exacerbations was significantly more frequent in the telemonitoring group (IRR 1.91, 95% CI 1.49-2.45).</p><p><strong>Conclusion: </strong>No effect of telemonitoring on hospitalizations for AECOPD was documented in this large cohort of patients with severe COPD. However, the telemonitoring group received significantly more treatment for moderate exacerbations. This risk of overtreatment should be considered when telemonitoring is used in the care of patients with COPD.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2361-2369"},"PeriodicalIF":2.7,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated with Initial Treatment Failure in Inpatients with Exacerbation of Chronic Obstructive Pulmonary Disease: A Cohort Study.","authors":"Noriko Kohyama, Kuniaki Hirai, Hironori Sagara, Miki Takenaka Sato, Masayuki Ohbayashi, Mari Kogo","doi":"10.2147/COPD.S516855","DOIUrl":"10.2147/COPD.S516855","url":null,"abstract":"<p><strong>Purpose: </strong>Some patients do not respond to initial therapy for exacerbation of chronic obstructive pulmonary disease (ECOPD), resulting in treatment failure that requires antimicrobial changes or advanced therapies. Appropriate treatment is possible if patients at a high risk of treatment failure at the start of treatment are properly identified. Therefore, this study examined the factors associated with initial treatment failure in patients with ECOPD.</p><p><strong>Patients and methods: </strong>We conducted a cohort study involving patients with ECOPD admitted to our hospital. The primary outcome was initial treatment failure, defined as a composite of treatment intensification for ECOPD and in-hospital mortality. Uni- and multivariate analyses were performed to identify the factors associated with initial treatment failure.</p><p><strong>Results: </strong>The analysis included data of 152 patients with a mean age of 76±8 years (mean±standard deviation); 81% of them were male patients. Treatment failure occurred in 26 (17%) patients. These included nine, two, one, and 14 patients who changed antimicrobial agents, received additional non-invasive positive pressure ventilation therapy due to non-improvement or symptom exacerbation, received additional invasive positive pressure ventilation therapy, and died in the hospital, respectively. Using multivariable analysis, home oxygen therapy (odds ratio, 5.335; 95% confidence interval, [1.542-18.457]), neutrophil count ≥7000 cells/µL (3.550; [1.007-12.519]), and acidemia (3.129; [1.009-9.698]) were significant factors associated with treatment failure. In patients treated with narrow-spectrum antibiotics as the initial antibacterial therapy, the treatment failure rate in patients receiving home oxygen therapy was significantly higher than in those receiving none.</p><p><strong>Conclusion: </strong>Home oxygen therapy, high neutrophil count, and acidemia on admission were risk factors for treatment failure. Particularly, patients receiving home oxygen therapy were at a higher risk of treatment failure with the use of narrow-spectrum antibiotics.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2349-2360"},"PeriodicalIF":2.7,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Daily Step Count, Step Frequency and the Risk of Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study Using NHANES Data.","authors":"Lindong Yuan, Zhen Tian, Xiaodong Jia, Zhe Chen","doi":"10.2147/COPD.S523574","DOIUrl":"10.2147/COPD.S523574","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is a major public health concern globally, and physical activity is considered a modifiable factor in its prevention.</p><p><strong>Purpose: </strong>This study examined the association between daily step count, step frequency, and the prevalence of chronic obstructive pulmonary disease (COPD) using nationally representative data.</p><p><strong>Patients and methods: </strong>A cross-sectional analysis was conducted using data from adults aged ≥40 years in the 2003-2006 National Health and Nutrition Examination Survey (NHANES). Participants wore accelerometers for 7 days to measure daily step count and three step frequency indicators: bout cadence, peak 30-minute cadence, and peak 1-minute cadence (steps/minute). Weighted logistic regression was used to assess associations with COPD, adjusting for demographic, behavioral, and health-related covariates. Sensitivity analyses and subgroup analyses were conducted to confirm robustness.</p><p><strong>Results: </strong>Among 3690 participants (representing ~26.8 million US adults), higher daily step count and step frequency were inversely associated with COPD prevalence. Compared to those taking <4000 steps/day, those taking ≥8000 steps/day had a 63% lower odds of COPD (OR 0.37, 95% CI 0.15-0.91; P for trend <0.001). Higher bout cadence (92.3-153.4 steps/minute) and peak 30-minute cadence (69.8-128.2 steps/minute) were also associated with significantly reduced COPD odds (ORs 0.30 and 0.33, respectively). Combined higher step count and frequency yielded a greater risk reduction. Restricted cubic splines indicated a nonlinear association, and ROC analysis showed moderate discriminatory power (AUC 0.71-0.75). Results remained robust in sensitivity analyses and across subgroups.</p><p><strong>Conclusion: </strong>In this cross-sectional study of US adults, higher daily step counts and greater walking cadence were associated with a lower prevalence of COPD. These findings support the relevance of step-based metrics in assessing COPD risk, although longitudinal studies are needed to establish causality.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2325-2335"},"PeriodicalIF":2.7,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long COVID in Elderly COPD Patients: Clinical Features, Pulmonary Function Decline, and Proteomic Insights.","authors":"Shuangyan Li, Hui Zhao, Min Zhang, Tingting Yuan, Di Chai, Zhengyin Shen, Chengfeng Qin, Yanming Li, Mingming Pan","doi":"10.2147/COPD.S520300","DOIUrl":"10.2147/COPD.S520300","url":null,"abstract":"<p><strong>Background: </strong>Elderly patients with chronic obstructive pulmonary disease (COPD) face a heightened risk of developing long coronavirus disease (COVID); however the exact clinical characteristics and underlying mechanisms remain unclear.</p><p><strong>Methods: </strong>We enrolled 85 elderly COPD patients, of whom 43 reported newly onset persistent fatigue (the most dominant complaint of long COVID) within 1 year after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and they were allocated to the Long-COVID group. The remaining 42 patients were assigned to the Control group. Patients completed questionnaires, pulmonary function tests, chest CT, routine laboratory tests, and blood proteomic analysis.</p><p><strong>Results: </strong>Long-COVID patients had a longer course of COPD (> 5 years, 76.8% vs 52.4%) and duration of SARS-CoV-2 infection (10.0 days vs 7.0 days) (All <i>P</i> < 0.05), higher symptom burden, worse pulmonary ventilation function and a more rapid decrease in DL_CO (All <i>P</i> < 0.05). Proteomic analysis indicated disruptions in inflammation and energy metabolism, potentially underlying long COVID in these patients. The machine learning model identified wheezing, the duration of SARS-CoV-2 infection, EIF2S3 (eukaryotic translation initiation factor 2 subunit gamma), current FEV1/FVC (%), and the course of COPD as key features distinguishing Long-COVID patients, and exhibited excellent performance.</p><p><strong>Conclusion: </strong>Elderly COPD patients with a longer COPD course and duration of COVID-19 are more prone to develop long COVID, with decreased pulmonary ventilation and diffusion ability. Disordered inflammation regulation and energy metabolism may be the potential mechanisms, highlighting the importance of monitoring inflammation and metabolic dysregulation in elderly COPD patients after recovery from COVID-19.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2337-2347"},"PeriodicalIF":2.7,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Clinical Stability and Mortality in COPD: A Longitudinal Study.","authors":"Wesley Teck Wee Loo, Si Yuan Chew, Jessica Han Ying Tan, Rui Ya Soh, Mariko Siyue Koh, Therese S Lapperre, Pei Yee Tiew","doi":"10.2147/COPD.S531435","DOIUrl":"10.2147/COPD.S531435","url":null,"abstract":"<p><strong>Background: </strong>There is no consensus on the definition of clinical stability in chronic obstructive pulmonary disease (COPD), and it is less frequently used as a treatment target compared to severe asthma. The factors that determine clinical stability and their effects on mortality are less well-studied in patients with COPD.</p><p><strong>Methods: </strong>To address this gap, we conducted a prospective longitudinal cohort study to identify predictors of two-year clinical stability, defined as no exacerbations and stable symptoms (<2 point change in CAT score from baseline), and the impact of comorbid cardiovascular disease (CVD) on clinical stability and mortality in COPD patients.</p><p><strong>Results: </strong>A total of 463 patients (mean age 71 ± 9 years) were enrolled in this study. The cohort was predominantly Chinese (81.7%) and 45.6% of participants were current smokers. The majority (55.7%) had a history of CVD. Approximately 36% of the cohort achieved clinical stability at one year, and one-third achieved stability at two years. Predictors of 2-year clinical stability included higher body mass index (BMI) (p<0.001), higher post-bronchodilator FEV1/FVC ratio (p=0.0132), fewer baseline exacerbations (p=0.007), absence of bronchiectasis (p=0.045), preserved hemoglobin levels (p=0.019), and successful smoking cessation (p=0.039). Notably, while 2-year clinical stability did not predict subsequent mortality, the presence of CVD was a significant predictor of 5-years mortality (HR 1.48, 95% CI 0.99-2.22; p=0.05).</p><p><strong>Conclusion: </strong>Our study identified several predictors of 2-year clinical stability in patients with COPD. However, clinical stability at 2 years did not predict subsequent mortality. These findings suggest that clinical stability and mortality are distinct outcomes that are driven by different sets of predictive variables. This underscores the need for a comprehensive approach to COPD management that not only addresses exacerbations and symptoms, but also considers a broader range of factors influencing survival, particularly the management of comorbidities such as cardiovascular disease.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2311-2324"},"PeriodicalIF":2.7,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12248741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Marijuana Use and Chronic Obstructive Pulmonary Disease: A Case Report.","authors":"Brenna S Ostertag, Kathryn W Hendrickson","doi":"10.2147/COPD.S520875","DOIUrl":"10.2147/COPD.S520875","url":null,"abstract":"<p><p>Marijuana smoking has become increasingly common in the United States and the world as more states and countries have legalized it for medical and recreational use. There are a number of carcinogens in marijuana smoke similar to those in tobacco smoke, and yet it has been difficult in the literature to find a causal relationship between marijuana smoking and chronic obstructive pulmonary disease (COPD). We present a patient whose main risk factor for emphysema is daily marijuana smoking for upwards of 35 years with no personal history of smoking tobacco, and no other obvious risk factors. Current studies have shown association with chronic marijuana smoking and various lung complaints, forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio, and inconsistently with chronic bronchitis. With this case, we add to the current body of literature that suggests a possible relationship between long-term, heavy marijuana use and COPD.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2305-2309"},"PeriodicalIF":2.7,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Crucial Role of the PPAR Signaling Pathway in the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease: An Analysis of Gene Expression and Macrophage Polarization.","authors":"Ling Zhang, Rong Guo, Haixia Wu, Abula Abudusalamu, Wei Ding, Dewei Li, Xuemei Wei, Lin Niu","doi":"10.2147/COPD.S518592","DOIUrl":"10.2147/COPD.S518592","url":null,"abstract":"<p><strong>Purpose: </strong>To explore the role of the peroxisome proliferator-activated receptor (PPAR) signaling pathway in chronic obstructive pulmonary disease (COPD) and identify potential biomarkers and therapeutic targets, given that COPD is a major global health burden and the specific molecular mechanisms of the PPAR pathway in COPD are not fully understood.</p><p><strong>Patients and methods: </strong>Gene expression data from the GEO database were analyzed to identify key genes and immune cells related to COPD. Peripheral blood samples were collected from COPD patients and healthy controls. Key genes were confirmed by PCR, and immune cells were characterized using flow cytometry.</p><p><strong>Results: </strong>Eight core genes associated with the PPAR signaling pathway were identified. NCOA1 and PPARGC1A were downregulated in COPD patients, while NCOR1, NRIP1, and SLC27A5 were upregulated. Receiver operating characteristic (ROC) curve analysis showed that NCOA1, NCOR1, and SLC27A5 have potential for COPD diagnosis. There was a significant increase in the proportion of M2 macrophages in COPD patients, indicating a shift in macrophage polarization towards the M2 phenotype. Genes within the PPAR signaling pathway were closely associated with macrophage polarization state.</p><p><strong>Conclusion: </strong>The research findings provide new biomarkers and potential therapeutic targets for the early diagnosis and personalized treatment of COPD, emphasizing the significant role of the PPAR signaling pathway in the pathogenesis of COPD.</p><p><strong>Clinical trial registry: </strong>The population study involved in this research has been registered under the (chictr.org.cn). Registry identifier: ChiCTR2400086268.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2287-2304"},"PeriodicalIF":2.7,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12248238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Mechanisms of Lijin Fang on Treg/Th17 Cell Imbalance in COPD Based on Network Pharmacology.","authors":"Zhan-Hua Li, Si-Ning Chen, Ling Pan, Rui Liu, Wei Liang, Mei-Qun Luo, Hai-Fei Liao, Jie Feng, Hao-Zhou Wang, Yue-Gan Huang, Jing-Hui Zheng","doi":"10.2147/COPD.S512469","DOIUrl":"10.2147/COPD.S512469","url":null,"abstract":"<p><strong>Background: </strong>Chronic Obstructive Pulmonary Disease (COPD) is chronic respiratory disease that severely affects patients' quality of life and is associated with high mortality rates. Investigating the imbalance between regulatory T cells (Tregs) and T helper 17 cells (Th17) in COPD treatment is crucial, as this imbalance plays a significant role in the disease's inflammatory processes. This study explores the therapeutic potential of the traditional Chinese medicine(TCM) formula, Lijin Fang (LJF), focusing on its ability to restore Treg/Th17 balance.</p><p><strong>Methods: </strong>We employed bioinformatics and in vitro cell experiments to analyze the active components and targets of LJF. Network pharmacology, differential gene expression, pathway enrichment, ROC model prediction, and immune infiltration analyses were conducted, followed by molecular docking studies. Rat peripheral blood mononuclear cells (PBMCs) were cultured and treated with cigarette smoke extract (CSE) and LJF-containing serum, with flow cytometry, ELISA, and Western blotting used to assess relevant markers.</p><p><strong>Results: </strong>Our findings demonstrate that treatment with (10% or 30%)LJF-containing serum significantly increased the proportion of Treg cells while concurrently decreasing Th17 cell populations in the 5%CSE-treated rat PBMC model (p<0.001). We observed a reduction in pro-inflammatory cytokines such as interleukin-17 (IL-17), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β), alongside an increase in the anti-inflammatory cytokine interleukin-10 (IL-10) (p<0.001). Additionally, potential therapeutic targets, including IL-10, potassium voltage-gated channel subfamily N member 4 (KCNN4), and Baculoviral IAP repeat-containing protein 3 (BIRC3), were identified. Molecular docking results indicated stable interactions between IL-10 and BIRC3 with the constituents of LJF.</p><p><strong>Conclusion: </strong>This study highlights LJF's anti-inflammatory potential in restoring the Treg/Th17 balance and regulating cytokine expression in COPD.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2227-2247"},"PeriodicalIF":2.7,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12242538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}